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Abstract
A robust oligonucleotide array-in-well hybridization assay using novel up-converting phosphor reporter technology was applied for
genotyping clinically relevant human adenovirus types. A total of 231 adenovirus-positive respiratory, ocular swab, stool and other spec-
imens from 219 patients collected between April 2010 and April 2011 were included in the study. After a real-time PCR amplification
targeting the adenovirus hexon gene, the array-in-well assay identified the presence of B03 (n = 122; 57.5% of patients), E04 (29;
13.7%), C02 (21; 9.9%), D37 (14; 6.6%), C01 (12; 5.7%), C05 (5; 2.4%), D19 (4; 1.9%), C06 (2; 0.9%), D08 (1; 0.5%), A31 (1; 0.5%) and
F41 (1; 0.5%) genotypes among the clinical sample panel. The typing result was obtained for all specimens that could be amplified
(n = 223; 97%), and specificity of the typing was confirmed by sequencing specimens representing each of the different genotypes. No
hybridization signal was obtained in adenovirus-negative specimens or specimens with other viruses (n = 30). The array-in-well hybrid-
ization assay has great potential as a rapid and multiplex platform for the typing of clinically relevant human adenovirus genotypes in dif-
ferent specimen types.
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Introduction
Human adenoviruses (hAdVs) belong to the genus Mastade-
novirus of the family Adenoviridae. There are presently 57
different hAdV types grouped into seven species A to G [1].
Different types cause a wide range of acute and chronic dis-
eases. Acute respiratory disease is predominantly caused by
the hAdV types C01, C02, E04, C05 and C06; occasionally
by types B03 and B07, whereas gastroenteritis is most com-
monly associated with the types F40 and F41 [2–4]. In all age
groups, the hAdV infection can include asymptomatic infec-
tion or may provoke serious illnesses such as pneumonia
(types B03, E04, B07, B14 and B21) or epidemic keratocon-
junctivitis (types D08, D19 and D37) [5–8]. Types E04 and
B07 have also caused severe outbreaks of respiratory illness
among military recruits [9]. Human AdVs can cause espe-
cially severe disease among infants, young children, immuno-
compromised patients and transplant recipients [10–12] and
hAdV infections occur worldwide as endemic, epidemic and
sporadic infections. Therefore, genotype-specific analysis is
important for epidemiological studies to provide information
on the incidence and distribution of infections by individual
hAdV types. Genotype identification is also necessary for the
detection of new strains and for understanding hAdV patho-
genesis.
Identification of serotypes is traditionally carried out by
neutralization with type-specific antisera [13]. The serologi-
cal detection methods are usually time-consuming, labour-
intensive and do not permit a reliable detection of all hAdV
serotypes. The availability of rapid diagnostic methods pro-
viding uncompromised analytical performance would allow
more efficient screening and identification of the pathogen.
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Today, genotyping by molecular methods such as PCR tar-
geting the hexon or fibre gene, followed by amplicon
sequencing or digestion of the amplicon with different
restriction enzymes, is often preferred over serotyping [14].
Recently, PCR-based microsphere array and reverse line
blot hybridization methods have been described for the
detection and differentiation of hAdV genotypes [15,16].
Another approach to multiplex detection is the microarray
analysis, which holds great potential for the detection and
typing of pathogens. Microarray techniques are flexible,
rapid and suitable for high throughput analysis. The sensitiv-
ity of PCR and the specificity of DNA hybridization can be
combined when the microarray technology is used for the
detection and typing of adenoviruses.
In our previous study [17], the feasibility of the up-con-
verting phosphor (UCP) reporter technology and anti-Stokes
photoluminescence detection with a new anti-Stokes photo-
luminescence imager was demonstrated in multi-analyte
assays. UCPs are inorganic lanthanide-doped crystals that
have a unique capability to convert infrared radiation to visi-
ble light via absorption of multiple photons. So, no autofluo-
rescence is produced from any biological material, enabling
sensitive assay [18]. We showed that real-time PCR and
array-in-well hybridization test platform could be used for
typing of hAdVs in standard 96-well microtitre plates.
In the present study, the array-in-well typing assay was
expanded and technically improved. White plates and nano-
sized (30 nm) up-converting nanoparticles (UCNPs) were
used instead of transparent 96-well microtitre well plates
and larger (>110 nm) UCP particles. The exposure time of
the white plate is only 1 s, making the assay implementation
more user-friendly [17]. New forward primers for real-time
PCR were designed because a longer amplicon with more
variation in the sequence was needed for the probe design.
New oligonucleotide probes were designed to type clinically
relevant members of hAdV groups A to F. The updated
array-in-well test platform successfully identified hAdV
genotypes from ocular swab, respiratory, stool and urine
specimens.
Materials and Methods
HAdV prototypes and clinical specimens
The prototypes of hAdV genotypes C01, C02, B03, E04,
C05, C06, B07, B11, B14, A18, A31, D36 and D37 were
originally obtained from the Centers for Disease Control
and Prevention (CDC, Atlanta, GA). The prototypes C01,
C02, B03, C05 and C06 were cultivated in the HeLa cell cul-
ture (human cervix carcinoma cell-line HeLa Ohio; Common
Cold Unit, Salisbury, Wiltshire, UK) and prototypes E04,
B07, B11, B14, A31, D36 and D37 were cultivated in the
A549 cell culture (human lung carcinoma cell-line A549;
American Type Culture Collection (ATCC), Rockville, MD)
for the isolation of viral DNA. The recent isolates of hAdV
genotypes D19 and B21 were kindly donated by HUSLAB,
Helsinki, Finland. The HeLa and A549 cells were maintained
in Eagle’s minimal essential and Ham’s F12 medium (both
from Gibco, Invitrogen, Carlsbad, CA), respectively, at 37C
in 5% CO2. Nasopharyngeal aspirate or swab (n = 86), ocu-
lar swab (n = 119), stool (n = 16), other types of respiratory
specimens (n = 3), others (n = 5) and unknown (n = 2) spec-
imens were selected from the processed clinical specimens
sent to the Department of Virology, University of Turku, for
hAdV detection between April 2010 and April 2011. All
specimens had tested positive for the hAdV using time-
resolved fluoroimmunoassay (16% of specimens) [19], single
PCR [20] or multiplex PCR detection (Seeplex; Seegene,
Seoul, Korea) (20%), or virus culture (64%). A total of 30
adenovirus-negative specimens including specimens with influ-
enza A or B virus (n = 5), parainfluenza virus 1 or 3 (n = 2),
coronavirus (n = 1), varicella zoster virus (n = 1), herpes sim-
plex virus type 1 or 2 (n = 6), rhinovirus (n = 3), enterovirus
(n = 1) or respiratory syncytial virus (n = 3) were also tested
to evaluate the specificity of the assay (see Supplementary
material, Data S1).
Synthesis, surface modification and conjugation of streptavi-
din to UCNPs
The nanocrystalline NaYF4:Yb
3+, Er3+ materials (crystallite
size 25 nm) were prepared with a modification of the
method reported earlier [21]. A description of the synthesis
and the surface modification of UCNPs can be found in the
Supplementary material (Data S2) [29,30]. The procedures
for coating UCNPs with streptavidin have been described
earlier [22].
Hexon gene amplification and sequencing
Nucleic acids were extracted from the specimens by using
the NucliSense easyMAG (BioMerieux, Boxtel, the Nether-
lands) or MagNA Pure 96 (Roche, Mannheim, Germany)
automated extractors and the extracts were stored at
)70C. An asymmetric real-time PCR amplification reaction
targeted to the hexon coding region was performed in a 25-
lL reaction mixture containing 0.1 lM of each generic for-
ward primer (ADHEX2F1, ADHEX2F2 and ADHEX2F3),
0.9 lM of 5¢-end biotinylated reverse ADHEX1R primer and
a 5-lL aliquot of extracted DNA (see Supplementary mate-
rial Data S3). A positive control of type C02 DNA and a no
template control were included in each PCR run. Reactions
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with melting curve analysis were carried out using a Max-
ima SYBR Green qPCR Master Mix (Fermentas, St Leon-
Rot, Germany) in a Rotor-Gene 6000 instrument (Corbett
Research, Mortlake, Victoria, Australia). Thermal cycling con-
sisted of initial denaturation and enzyme activation at 95C
for 15 min, followed by 40 cycles of denaturation at 94C
for 15 s, annealing at 50C for 60 s, and extension at 72C
for 45 s, and final melting curve generation steps from 72 to
95C with 1C for 5 s increments. The PCR products were
used as such in the hybridization assay [17] or, for sequenc-
ing, were purified (QuickClean, PCR Purification Kit; Gen-
Script, Piscataway, NJ) and eluted with a 30 lL volume of
nuclease-free sterile water. The amplicons were sequenced
in the DNA Sequencing Service Laboratory of the Turku
Centre for Biotechnology (Turku, Finland) using the AD-
HEX2F1, ADHEX2F2 or ADHEX2F3 primer.
Oligonucleotide microarrays
Oligonucleotide probes 1–16 for the hAdV genotypes C01,
C02, B03, E04, C05, C06, B07, D08, B11/B14, D19, B21,
A31, D36, D37 and F40/F41 were designed using published
hexon sequences [23] (Data S3). The HPLC-purified oligonu-
cleotides were obtained from http://www.Biomers.net (Ulm,
Germany). To improve the probe availability for hybridiza-
tion, the oligonucleotides were synthesized with three extra
T/C nucleotides as spacers at their 5¢ ends before the termi-
nal amino-link C6 group. Probes g1, g2, g3, g4, g5, g6, g7 and
g8 were used for the generic detection of hAdVs (Data S3).
Any hAdV genotype was aimed to be identified by at least
one generic probe and each target genotype by one or more
specific probes in a unique pattern. Microarrays in white
96-well microtitre plates (Nunc, Thermo Fisher Scientific,
Roskilde, Denmark) were prepared at the VTT Medical
Biotechnology Centre (Turku, Finland).
Hybridization, imaging and image analysis
The hybridization assay, imaging the array and the image
analysis were carried out as described earlier [17]. Briefly,
16 hAdV genotype-specific 5¢-amino-modified probe spots
were printed covalently as three replicates on the bottom of
a white 96-well microtitre plate. The oligonucleotide probes
were hybridized with the denatured biotinylated PCR prod-
ucts and the bound biotinylated products were detected
with streptavidin-coated UCNPs (see Supplementary mate-
rial, Data S4). The array-in-well assay was measured with an
anti-Stokes photoluminescence imager [17]. The device was
constructed for multiplexed testing with laser diode excita-
tion and CCD image sensor, with a minor change in the
optics: a Round Diffuser (RD-206-I-Y-A; Holo/Or., Rechovot,
Israel) was added between the collimator and the excitation
filter. The parameters used in this study were: 2· binning,
1 s exposure per well and 7 W laser power. Genotypes
were called according to the pattern of fluorescent probe
spots.
Results
Hexon gene amplification
The combination of one reverse primer and three forward
primers specific to a part of the conserved hexon gene
region allowed amplification of hAdV genotypes belonging to
different species (A to F). Asymmetric real-time PCR ampli-
fied nucleic acids from all the prototypes used in the study.
Human AdV DNA was amplified in 223 (97%) of the 231
clinical specimens that had originally tested positive for
hAdV. The sensitivity of the real-time PCR was determined
with type C02, which was detected at concentrations of
below ten copies per reaction (data not shown). The plot of
cycle threshold (Ct) values for the prototypes and clinical
specimens is shown in Fig. 1. Adenovirus negative clinical
specimens frequently showed non-specific late amplifications
(Ct > 30) complicating hAdV detection by the PCR method
alone.
Human AdV genotypes
Eleven different hAdV genotypes: C01, C02, B03, E04, C05,
C06, D08, D19, A31, D37 and F41 were identified among
the hAdV-positive clinical specimens. The microarray pro-
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FIG. 1. Distribution of real-time PCR cycle threshold (Ct) values for
the human adenovirus (hAdV)-typed specimens and unspecific ampli-
fication of hAdV-negative specimens or specimens with other
viruses. DNA from prototypes (stars) was extracted from culture
supernatants with varying level of infection and their Ct values do
not reflect the assay sensitivity.
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vided a clear hybridization pattern for each hAdV prototype
and amplified clinical specimen (Fig. 2). Cross-reactions with
other viruses or hAdV-negative specimens (n = 30) were not
observed. A non-targeted prototype A18 showed strong
hybridization signal with generic probes only. The array was
not able to discriminate between the B11 and B14, because
the targeted hexon sequence showed 98% sequence homol-
ogy (five mismatches in the 270 bp region) between these
two types. Randomly selected samples (n = 22) representing
all detected genotypes were sequenced to assure the assay
result. In all cases, the genotype revealed by the microarray
was consistent with the sequencing result.
Study population/age and gender distributions
Fever, cold, cough, pharyngitis and conjunctivitis were the
most commonly reported clinical manifestations among the
patients. The most prevalent hAdV genotypes were B03
(n = 122; 58% of all specimens), E04 (29; 14%), C02 (21;
10%) and D37 (14; 7%). In addition, several other hAdV
genotypes were identified among the clinical sample panel:
C01 (n = 12), C05 (n = 5), D19 (n = 4), C06 (n = 2), D08
(n = 1), A31 (n = 1) and F41 (n = 1). One female patient had
subsequent infections with genotypes C02 and B03 6 months
apart. The hAdV genotypes C01, C02, C05 and C06 were
mainly detected in children under 4 years of age. The geno-
type A31 was detected in one immunocompromised female
patient only. Ten co-infected specimens were detected
among the sample panel. One boy had a co-infection of
hAdV genotype C05 and coxackievirus 24 detected from
stool. The other nine co-infections were detected in girls
and boys (under the age of 14 years) from respiratory speci-
mens: hAdV genotype C02 and rhinovirus; B03 and parainflu-
enza virus type 3; C01 and respiratory syncytial virus; C01
and influenza virus B; C01 and rhinovirus; C02 and influenza
virus B; C01 and respiratory syncytial virus; C01 and meta-
pneumovirus; C02 and metapneumovirus. The age range of
the patients was from <1 to 67 years with a median age of
25 years. There were 100 (47%) male patients and 111
(53%) female patients in this study. Most hAdV infections
were prevalent in adults: 125 (59%) patients were aged 18
or more and 73 (60%) of them were women. The hAdV
genotype B03 was distributed throughout all age groups
(Fig. 3).
Specimen types/seasonal distributions
The hAdV genotypes detected in ocular swabs were B03
(n = 79; 68%), E04 (18; 15%), D37 (15; 13%), D19 (4; 3%)
and D08 (1; 1%). The hAdV genotypes detected in respira-
tory (NP in Fig. 4) specimens were B03 (n = 40; 47%), C02
(19; 22%), C01 (11; 13%), E04 (10; 12%), C05 (3; 4%) and
C06 (2; 2%) (Fig. 4). Human AdV infections were prevalent
throughout the year but peaked in September and October
2010 (Fig. 5).
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FIG. 2. (a) The array-in-well layout. The symbols C1, C2 and C3
denote generic control probe spots and spot numbers 1–16 corre-
spond to the specific probes listed in the Supplementary material,
Data S3. The probe number does not refer to the human adenovirus
(hAdV) genotype. (b) Hybridization patterns of representative proto-
types from hAdV genotypes C01, C02, B03, E04, C05, C06, B07,
B11, B14, D19, B21, A31, D36, D37, clinical specimens D08 and F41
(genotypes were determined by sequencing), non-targeted hAdV
prototype A18, and hAdV-negative specimen. The assignment to
hAdV type in unknown specimens was based on the hybridization
pattern in comparison to that of the known types. Genotype C02
dilution 1 (dil.1): 5 · 105 copies, dil.2: 500 copies, and dil.3: 5 copies
per PCR, respectively.
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Discussion
The main purpose of this study was to demonstrate the
capability of the array-in-well hybridization assay to identify
the hAdV genotypes prevalent in patients in Finland during
the study period. We used asymmetric real-time PCR to
produce amplicons that were typed in the hybridization assay
using UCNP-label and obtained a genotyping result in 97% of
the specimens.
The developed array-in-well hybridization assay has
broader type selection than many other published hAdV typ-
ing assays based on hybridization [16,24] except for the
reverse line blot hybridization method [15]. Although not all
hAdV prototypes were available for in vitro testing, in silico
analyses gave a specific pattern for most of the targeted
genotypes. Predictably, F40 would not be differentiable from
F41 just as B14 was not differentiable from B11. Another
weakness is that the PCR method alone is not sufficiently
specific for hAdV detection. However, the assay has some
attractive advantages compared with other assays. First, the
hybridization assay is performed in 96-well microtitre plates
allowing the use of common laboratory equipment, and the
assay is easy to carry out. Second, microtitre plates enable
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the analysis of 96 samples at one time. When necessary, it is
also possible to add more probes to the 96-well microtitre
plate, enabling the typing of additional hAdV genotypes in
one assay.
During the study period, an outbreak of hAdV type B03
infections occurred in the autumn of 2010. Type B03 was
commonly associated with conjunctivitis (n = 79; 68%), and
respiratory diseases (40; 47%). A study conducted in 2010
[25] reported that restriction enzyme analysis identified
three genetic variant types, including two newly described
variants, Ad3a50 and Ad3a51. New variant types could be a
reason for the high incidence of B03 infections in this study.
The predominant adenovirus genotypes differ between
countries or regions and change over time. In 2006 and
2007, the hAdV type B14 emerged as a significant contribu-
tor to acute respiratory disease and severe pneumonias in
the USA and at military recruit training centres across the
USA [26]. The rarely identified B14 has also emerged in Eur-
ope [27,28]. In the present study, neither B14 nor B11,
which are indistinguishable in the current assay, was detected
among the clinical specimens.
In this study, a multiplex assay platform was generated to
identify all common epidemic hAdV genotypes. The devel-
oped array-in-well hybridization assay with specific probes
offers a rapid (1 day from sample preparation to imaging the
hybridized microarray) tool for the genotyping of significant
hAdV types involved in different clinical conditions.
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